Dr. Loeb on the Impact of Additional Testing for Prostate Cancer

Video

Stacy Loeb, MD, assistant professor of Urology and Population Health at New York University, discusses the impact of different genomic tests for patients with prostate cancer.

Stacy Loeb, MD, assistant professor of Urology and Population Health at NYU Langone Health's Perlmutter Cancer Center, discusses the impact of different genomic tests for patients with prostate cancer.

Patients now have more testing options than before, states Loeb. Patients no longer need to rely on a single biopsy, as there are multiple tests which will help physicians determine the most beneficial treatment and management options for the patient.

Related Videos
Rita Nanda, MD
Vikram Narayan, MD
Daniel Olson, MD
Vishal Patel, MD, FAAD, FACMS, associate professor, Dermatology, George Washington (GW) School of Medicine & Health Sciences
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS